Transcranial Treatments in Eating Disorders

Novel Transcranial Treatments to Modulate Taste Reward and Body Perception Pathways in Eating Disorders

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02535780

Enrollment

Registered

2015-08-31

Start date

2015-08-31

Completion date

2016-06-30

Last updated

2016-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa, Bulimia Nervosa

Brief summary

The primary aim of this study is to study how Repetitive Transcranial Magnetic Stimulation (rTMS) tailored to specific anorexia nervosa (AN) or bulimia nervosa (BN) brain activation alterations will promote recovery and to study how inhibitory tDCS (Transcranial Direct Current Stimulation) will reduce symptoms of body image distortion in a second sample of AN and BN groups.

Interventions

PROCEDURETranscranial magnetic stimulation

TMS

PROCEDURETranscranial direct current stimulation

tDCS

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Anorexia Nervosa subjects: * Meets DSM-5 criteria for anorexia nervosa (AN) either binge-eating/purging type or restricting-type: * Intense fear of gaining weight or becoming fat, even though underweight. * The ability to undergo an MRI, fMRI or other similar procedure requiring spending time in an enclosed space * Bulimia Nervosa subjects: * Meet DSM-5 criteria for bulimia nervosa (BN): * Self-induced vomiting; misuse of laxatives, diuretics, enemas, medication, fasting, excessive exercise.

Exclusion criteria

* Electrolyte, blood count or kidney or liver function abnormalities. * No symptoms of alcohol or other substance abuse or dependence in the past 3 months, * No previous or current organic brain syndromes, dementia, psychotic disorders, somatization disorders, or conversion disorder, head trauma, indication of mental retardation or pervasive developmental disorder. * No antipsychotics, tricyclic antidepressants or Wellbutrin or other medication that may lower the seizure threshold. * Claustrophobia.

Design outcomes

Primary

Measure	Time frame	Description
taste reward brain function activation confirmed by Functional magnetic resonance imaging (fMRI)	3 years	Change in brain activation to taste reward paradigm

Secondary

Measure	Time frame	Description
Change in self-reported measures related to eating disorder thoughts and behaviors	3 years	Self Assessment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026